Investor Day Presentations

  • Our vision and opportunity - Better health through genetic insights

    Paul J. Diaz

    President & CEO

    Paul J. Diaz

    President & CEO

    Paul J. Diaz, was named president, chief executive officer and member of the Myriad Genetics board of directors on August 13, 2020. Paul was most recently a partner at Cressey & Company (2016-2020), a private investment firm headquartered in Chicago, Illinois, which currently manages over $3.0 billion in committed capital. Cressey & Company is a healthcare focused middle-market private equity firm with over 30 years of success investing in and helping to build high quality healthcare businesses. Paul is the former president and chief executive officer and vice chairman of Kindred Healthcare, Inc. (NYSE:KND) (2002-2016) a Fortune 500 Company and one of the largest providers of healthcare services in the United States. At the time, Kindred had revenues of $7.2 billion, rehabilitation hospitals, sub-acute units, home health and hospice agencies and contract rehabilitation locations. For six years in a row, during his tenure as CEO, Kindred was ranked one of the Most Admired healthcare companies in the U.S. by Fortune magazine. Paul currently serves on the board of directors of DaVita (NYSE: DVA), the board of trustees of Johns Hopkins Medicine (where he serves as chair of Johns Hopkins Healthcare), and the board of visitors of the Georgetown University Law Center. He was formerly on the board of directors of PharMerica Corporation (NYSE: PMC), and previously served on the board of the federation of American Hospitals, and the Bloomberg School of Public Health at John Hopkins University. While chief executive officer of Kindred, Paul was a member of the Business Roundtable and the Wall Street Journal CEO Council. Modern Healthcare magazine named Paul one of the 100 Most Influential People in Healthcare and named him one of the top 25 Minority Executives in Healthcare for numerous years. In addition, Hispanic magazine named Paul one of the 25 Best Latinos in business in multiple years. Paul earned a bachelor’s degree in Finance and Accounting from American University’s Kogod School of Business and a law degree from Georgetown University Law Center in Washington, D.C.

  • Executing to win - Expanding commercial sales and marketing capabilities to increase access to genetic testing and drive growth

    Mark S. Verratti

    Chief Commercial Officer

    Mark S. Verratti

    Chief Commercial Officer

    Mark Verratti was promoted to chief commercial officer of Myriad Genetics in April 2022, responsible for accelerating the enterprise growth team to enhance commercial and marketing capabilities, gain new customer insights, and enhance demand generation. In addition to his expanded enterprise role, he also continues to oversee Myriad’s Mental Health business, including the GeneSight® pharmacogenomics test. Mr. Verratti has more than 20 years of experience leading large commercial organizations in the pharmaceutical and medical device industries. He has held senior and general management positions with Cyberonics/LivaNova leading teams in over 70 countries. He received a B.S. in Life Sciences with a minor in Physiology from The Pennsylvania State University.

  • Engaging our team - Driving service and operational excellence Key Performance Indicators

    Nicole Lambert

    Chief Operating Officer

    Nicole Lambert

    Chief Operating Officer

    Nicole Lambert is chief operating officer of Myriad Genetics, promoted in December 2021. She joined Myriad Genetics in June 2001 and continues to serve as Group President of Myriad Oncology, Women’s Health and International businesses. Previously, she served as general manager for the Oncology and Urology business units and vice president of Dermatology. Prior to joining Myriad, she was a genetic counselor at LabCorp. Mrs. Lambert received her bachelor’s degree in Biology and Sociology from Boston College and earned her master’s in genetic counseling from Mt. Sinai School of Medicine at New York University. She currently serves a member of the Board of Directors of Arcus Biosciences.

  • Enhancing core lab capabilities - Supporting growth, productivity, and innovation Lab of the Future

    Nicole Lambert

    Chief Operating Officer

    Nicole Lambert

    Chief Operating Officer

    Nicole Lambert is chief operating officer of Myriad Genetics, promoted in December 2021. She joined Myriad Genetics in June 2001 and continues to serve as Group President of Myriad Oncology, Women’s Health and International businesses. Previously, she served as general manager for the Oncology and Urology business units and vice president of Dermatology. Prior to joining Myriad, she was a genetic counselor at LabCorp. Mrs. Lambert received her bachelor’s degree in Biology and Sociology from Boston College and earned her master’s in genetic counseling from Mt. Sinai School of Medicine at New York University. She currently serves a member of the Board of Directors of Arcus Biosciences.

  • Tech-enabled commercial capabilities - Improving the customer experience and driving growth

    Kevin R. Haas, Ph.D.

    Chief Technology Officer

    Kevin R. Haas, Ph.D.

    Chief Technology Officer

    Kevin R. Haas, chief technology officer, joined Myriad Genetics in May 2013. Previously, he was vice president of Bioinformatics. Dr. Haas also serves on the Board of Directors and is vice president for USA Triathlon, the non-profit national governing body for the sport. Dr. Haas received a B.S. from University of Wisconsin-Madison and a Ph.D. in Chemical Engineering from University of California-Berkeley, where he worked on molecular simulation and machine learning to study protein dynamics from single molecule fluoresce. He has co-authored 16 peer reviewed publications and eight patent applications.

  • What’s next - Innovating and elevating our product pipeline

    Dale Muzzey, Ph.D.

    Chief Scientific Officer

    Dale Muzzey, Ph.D.

    Chief Scientific Officer

    Dale Muzzey, Ph.D., is chief scientific officer of Myriad Genetics. He joined the company in April 2014. Previously, he was senior vice president of R&D. Before joining Myriad, he was a postdoctoral scholar at University of California, San Francisco, with a fellowship from the Damon Runyon Cancer Research Foundation. Dr. Muzzey received a B.A. with honors in Biochemical Sciences from Harvard University and a Ph.D. in Biophysics from Harvard University. His thesis research applied signal-processing techniques to cellular signal-transduction cascades to better understand how response dynamics revealed insight into network architecture.

  • Delivering value - Long-term growth and profitability

    Bryan Riggsbee

    Chief Financial Officer

    Bryan Riggsbee

    Chief Financial Officer

    Bryan Riggsbee, chief financial officer, joined Myriad Genetics in October 2014. He previously served 10 years with Laboratory Corporation of America (LabCorp) where his most recent position was as senior vice president of Corporate Finance with responsibility for the financial planning and analysis and treasury functions. Prior to LabCorp, Mr. Riggsbee served in various finance roles with General Electric and began his career in the audit division of KPMG. He received a B.A. degree in Accounting from North Carolina State University, a B.A. degree in Political Science from the University of North Carolina at Chapel Hill and an M.B.A. from Northwestern University. Mr. Riggsbee is a Certified Public Accountant licensed in the State of North Carolina.

  • View Full Investor Day Presentation

Labs of the Future

Myriad Genetics is creating state-of-the art Labs of the Future to analyze genetic test results and deliver more timely, accurate results to healthcare providers and patients.

Voice of the Customer

We are focused on building trust with our customers. As a trusted partner, we are here to listen, innovate, and improve healthcare outcomes for patients and the providers that care for them.